|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||312.497 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
JWH-133, alongside WIN 55,212-2 and HU-210, is responsible for preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers . This anti-inflammatory action is induced through agonist action at the CB2 receptor, which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids at this receptor completely abolish neurotoxicity related to microglia activation in rat models.
As the U.S. Drug Enforcement Administration criminalizes any extract "containing one or more cannabinoids," JWH-133 is a scheduled substance in the U.S. This is despite the low potential for abuse relative to its sister compounds such as JWH-018, as JWH-133 is selective for the non-psychoactive CB2 receptor and thus lacks significant psychoactive effects.
- Caffarel MM, Andradas C, Mira E, Pérez-Gómez E, Cerutti C, Moreno-Bueno G, Flores JM, García-Real I, Palacios J, Mañes S, Guzmán M, Sánchez C (July 2010). "Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition". Molecular Cancer. 9: 196. doi:10.1186/1476-4598-9-196. PMC 2917429. PMID 20649976. Lay summary – NORML.
- "PART 1308 - Section 1308.11 Schedule I". www.deadiversion.usdoj.gov. Retrieved 2020-01-08.
- Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML (February 2005). "Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation". The Journal of Neuroscience. 25 (8): 1904–13. doi:10.1523/JNEUROSCI.4540-04.2005. PMC 6726060. PMID 15728830.</ref>